KZR Kezar Life Sciences, Inc.: רווח נקי למניה ב-12 החודשים האחרונים

Kezar Life Sciences (KZR) faces testing uncertainty and cash burn, which is impacting profitability. Analyzing the rolling trailing twelve-month earnings per share on GURU.Markets, we find that the -6.13 level reflects the current value. The biotech's prospects depend on the efficacy of its immunotherapy, while high R&D costs and safety risks necessitate the pursuit of external capital.
פילוחי נתונים אנליטיים מרוכזים עבור Kezar Life Sciences, Inc (KZR)

EPS TTM serves as the key basis for determining the real value of a business. This metric is calculated as the ratio of total annual net income to the number of shares outstanding. By analyzing the trailing twelve-month earnings per share, an investor tracks profitability trends without gaps between reports. For the biotech company Kezar Life Sciences (KZR), this indicator reflects the efficiency of investments in immuno-oncology. Growth in this metric confirms the successful commercialization of patents and scientific discoveries.